Gabapentin Role in Post-Operative ACDF Pain Management
Do not routinely use gabapentin for postoperative pain management after ACDF. The most recent high-quality evidence from 2026 demonstrates that gabapentin use following ACDF is associated with increased—not decreased—opioid consumption and higher complication rates, directly contradicting its presumed benefit in this setting 1.
Evidence-Based Recommendation
The 2026 retrospective propensity-matched analysis of 32,455 patients per group found that gabapentinoid use after ACDF was associated with:
- Persistently higher opioid consumption at every interval through 5 years (2.29% vs 0.51% at 5 years, RR 4.61, P < 0.001)
- Greater risk of pneumonia and respiratory failure across multiple timepoints
- No demonstrable benefit in multimodal pain regimens for ACDF 1
This large-scale, recent study specifically examining ACDF patients provides the strongest evidence against routine gabapentin use in this surgical population.
Context from General Surgical Guidelines
While general surgical guidelines suggest gabapentinoids can be considered as components in multimodal analgesia 2, these recommendations carry only moderate strength with moderate quality evidence and are not procedure-specific. Critically, the 2019 French expert panel guidelines explicitly state: "The systematic use of gabapentinoids preoperatively is not recommended for postoperative pain management" 3.
Key Nuances from Other Surgical Populations:
When gabapentinoids showed limited benefit:
- In caesarean sections with robust multimodal regimens (intrathecal morphine + NSAIDs + acetaminophen), no significant benefits were reported with gabapentin 4
- In total hip arthroplasty, repeated doses showed some pain reduction but were not recommended as routine medication due to clinically relevant side-effects (dizziness, sedation) 5
Side effects consistently reported across studies:
Recommended Multimodal Approach for ACDF
Instead of gabapentin, prioritize:
Acetaminophen - Strong recommendation as first-line adjunct, better and safer than other drugs when started at beginning of postoperative period 2
NSAIDs - Strong recommendation with high-quality evidence for multimodal analgesia (if no contraindications) 2
Opioids - Use lowest effective dose as needed, with pharmacological step-up approach 2
Consider postoperative physical therapy - Recent 2026 evidence shows PT within 2 months post-ACDF significantly reduces opioid prescription risk (RR: 0.739) and mean prescriptions (1.9 vs 2.2) in the first postoperative year 6
Critical Pitfalls to Avoid
- Do not assume gabapentin benefits from neuropathic pain studies translate to acute postoperative ACDF pain - The 2026 ACDF-specific data contradicts this assumption 1
- Do not use gabapentin routinely "just because it's part of multimodal analgesia" - The ACDF population shows harm, not benefit 1
- Be aware that 15.6% of patients continue gabapentinoid purchases postoperatively - This represents potential for prolonged unnecessary medication exposure 7
Special Consideration for Neuropathic Pain
The only strong recommendation for gabapentinoids is when documented neuropathic pain is present - in this specific context, use gabapentin/pregabalin/carbamazepine with opioids for neuropathic pain management 8. However, this is distinct from routine postoperative pain management after ACDF.
The evidence is clear: gabapentin should not be part of routine multimodal analgesia protocols for ACDF patients, as it increases rather than decreases opioid consumption and complications 1.